{"organizations": [], "uuid": "989152be19abd17433c4955d9488cb2c62f72026", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "au.finance.yahoo.com", "main_image": "https://s.yimg.com/bt/api/res/1.2/W0JQUtF1.PsUg11NkhDYXg--/YXBwaWQ9eW5ld3NfbGVnbztxPTc1O3c9NjAw/http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20150904005163r1&amp;sid=5030&amp;distro=ftp.cf.png", "site_section": "http://finance.yahoo.com/rss/headline?s=NVS", "section_title": "Yahoo! Finance: NVS News", "url": "https://au.finance.yahoo.com/news/research-markets-investigation-report-chinas-093400756.html", "country": "US", "title": "Research and Markets: Investigation Report on China's Octreotide Market, 2010-2019 - Yahoo7 Finance Australia", "performance_score": 0, "site": "yahoo.com", "participants_count": 1, "title_full": "Research and Markets: Investigation Report on China's Octreotide Market, 2010-2019 - Yahoo7 Finance Australia", "spam_score": 0.0, "site_type": "news", "published": "2015-09-30T03:00:00.000+03:00", "replies_count": 0, "uuid": "989152be19abd17433c4955d9488cb2c62f72026"}, "author": "Research and Markets", "url": "https://au.finance.yahoo.com/news/research-markets-investigation-report-chinas-093400756.html", "ord_in_thread": 0, "title": "Research and Markets: Investigation Report on China's Octreotide Market, 2010-2019 - Yahoo7 Finance Australia", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "DUBLIN--(BUSINESSWIRE)-- Research and Markets ( http://www.researchandmarkets.com/research/gv8kpd/investigation ) has announced the addition of the \"Investigation Report on China's Octreotide Market, 2010-2019\" report to their offering. \nFirst approved to be sold in 1996, octreotide was developed by Novartis AG under the trade name of Sandostatin. The approved indications at that time were acromegaly, diarrhoea and pancreatic cancer. Due to its sure efficacy and various indications, octreotide has become one of the most highly stressed biosimilar compounds. Octreotide has remained a steady growth ever since its listing and its sales value surpassed USD 1000 million in 2007. Sandostatin's US patent expired in June 2014. Although the generic drug of octreotide made by Sun Pharmaceutical Industries Ltd got FDA's approval in 2008, Novartis's octreotide still brought in sales revenue of USD 1589 million in 2013. \nAfter Octreotide made by Novartis entered China in 2004, many local generic drugs came into the market successively. Octreotide has undergone a fast development in China with annual sales value rising from CNY 100 million in 2005 to CNY 466 million in 2014 and CAGR reaching up to 15.8% during the period of 2005-2014. Octreotide enjoys a vast demand in China. Novartis AG (Sweden), Chengdu Tiantaishan Pharmaceutical Co., Ltd, Sinopharm A-THINK Pharmaceutical Co., Ltd, Peking Sunho Pharmaceutical Co., Ltd and Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd all take up certain shares in the Chinese market, among which Novartis AG (Sweden) has the largest market share of over 70%, sales value in 2014 reaching up to CNY 334 million in 2014. \nKey Topics Covered: \n1 Related Concepts of Octreotide \n2 Market Profile of Octreotide in China \n3 Survey on Sales Status of Octreotide in China, 2010-2014 \n4 Survey on Market Share of Major Manufacturers of Octreotide in China, 2010-2014 \n5 Survey on Dosage Forms of Octreotide in China, 2010-2014 \n6 Reference Price of Octreotide in Chinese Hospitals in 2014 \n7 Major Manufacturers of Octreotide in Chinese Market, 2010-2014 \n8 Market Outlook of Ooctreotide in China, 2015-2019 \nCompanies Mentioned \n- Novartis AG (Switzerland) \n- Chengdu Tiantaishan Pharmaceutical Co., Ltd \n- Sinopharm A-THINK Pharmaceutical Co., Ltd \n- Peking Sunho Pharmaceutical Co., Ltd \n- Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd \nFor more information visit http://www.researchandmarkets.com/research/gv8kpd/investigation \n\nView source version on businesswire.com: http://www.businesswire.com/news/home/20150904005163/en/ \nContact: Research and Markets\nLaura Wood, Senior Manager\npress@researchandmarkets.com \nFor E.S.T. Office Hours Call 1-917-300-0470\nFor U.S./CAN Toll Free Call 1-800-526-8630\nFor GMT Office Hours Call +353-1-416-8900\nU.S. Fax: 646-607-1907\nFax (outside U.S.): +353-1-481-1716\nSector: Pharmaceuticals", "external_links": [], "published": "2015-09-30T03:00:00.000+03:00", "crawled": "2015-09-30T08:59:23.311+03:00", "highlightTitle": ""}